HT
BMRN icon

Headlands Technologies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Headlands Technologies’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,754
Closed -$639K – 747
2025
Q4 		$639K Buy
+10,754
New +$585K 0.05% 358
2025
Q3 		– Sell
-11,886
Closed -$653K – 688
2025
Q2 		$653K Buy
+11,886
New +$700K 0.08% 261
2025
Q1 		– Sell
-1,787
Closed -$117K – 1160
2024
Q4 		$117K Buy
+1,787
New +$120K 0.01% 636
2024
Q2 		– Sell
-5,692
Closed -$497K – 1172
2024
Q1 		$497K Buy
5,692
+4,411
+344% +$395K 0.12% 192
2023
Q4 		$124K Buy
1,281
+1,159
+950% +$103K 0.04% 352
2023
Q3 		$10.8K Sell
122
-1,857
-94% -$165K 0.01% 686
2023
Q2 		$172K Buy
+1,979
New +$186K 0.05% 310

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's BMRN Position: Q1 2026 in Review

Headlands Technologies sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 10,754 shares — an estimated $639K sold.

Headlands Technologies first reported a position in BMRN in Q2 2023 and held it in 7 quarters. The position peaked at $653K in Q2 2025. 557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Headlands Technologies reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 10,754 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $639K.
  • Headlands Technologies first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • Headlands Technologies's BioMarin Pharmaceuticals position peaked at $653K in Q2 2025.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.